With the undeniable excitement in the BCMA field over the past few months, the BCMA-Targeted Therapies Summit returns to the space to equip you with the knowledge and connections to revolutionize your BCMA-centered pipeline.

Pick the brains of 90+ academic and industry pioneers at the first physical edition of the only meeting dedicated to supercharging transformative next generation BCMA-targeted therapies into the clinic, navigating the complex landscape and optimizing clinical strategy to revolutionize treatment of multiple myeloma and beyond.

Hear from leading speakers including:

• • Suzette Girgis, Senior Director & Head of Clinical Pharmacology & Hematologic Malignancies, Johnson & Johnson Services
  • Eric Fedyk, Global Program Leader of BCMA Assets, 2seventy bio
  • David DiLillo, Director, Immuno-Oncology, Regeneron
  • Brandon Kremer, Group Senior Medical Director, Clinical Development Lead, GlaxoSmithKline
  • Nathan Martin, Translational Scientist & Project Lead, Bristol Myers Squibb
  • Mike Damore, Director & Lead – Translational Oncology, Pfizer
  • Chetasi Talati, Medical Director, AbbVie
  • Dexiu Bu, Senior Principle Scientist, CART group, Immuno-Oncology & Hematology, Novartis
  • Faiza Zafar, Senior Medical Science Liaison, Legend Biotech

Take a look at the full event guide to learn more.